(R)-benzyl 2-((2S,3S)-3-((R)-1-hydroxyethyl)-4-oxoazetidin-2-yl)propanoate | 135038-17-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酰胺类
• 英文名称: (R)-benzyl 2-((2S,3S)-3-((R)-1-hydroxyethyl)-4-oxoazetidin-2-yl)propanoate
• 英文别名: benzyl (2R)-2-[(2S,3S)-3-[(1R)-1-hydroxyethyl]-4-oxoazetidin-2-yl]propanoate
• CAS: 135038-17-4
• 化学式: C₁₅H₁₉NO₄
• 分子量: 277.32
• InChiKey: VRTDFLRJJCGCEC-FPQZTECRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (R)-benzyl 2-((2S,3S)-3-((R)-1-hydroxyethyl)-4-oxoazetidin-2-yl)propanoate 在 吡啶 、 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 3.0h， 生成 (2R)-2-[(2S,3S)-3-[(1R)-1-(acetyloxy)ethyl]-4-oxoazetidin-2-yl]propanoic acid
  参考文献：
  名称：

  NOVEL BETA LACTAMS AS MODULATORS OF GLUTAMATE UPTAKE AND METHODS FOR USE THEREOF

  摘要：

  本发明的药物组合物包括化合物、组合物、用于治疗药物成瘾、药物戒断以及涉及谷氨酸稳态失调的疾病或症状的方法。

  公开号：

  US20160229841A1
• 作为产物：
  描述：

  (R)-2-[(2S,3S)-3-(2-Bromo-acetyl)-1-(tert-butyl-dimethyl-silanyl)-4-oxo-azetidin-2-yl]-propionic acid benzyl ester 在 偶氮二异丁腈 盐酸 、 sodium tetrahydroborate 、 三正丁基氢锡 、 sodium iodide 作用下， 以 甲醇 、 丙酮 、 甲苯 为溶剂， 反应 4.5h， 生成 (R)-benzyl 2-((2S,3S)-3-((R)-1-hydroxyethyl)-4-oxoazetidin-2-yl)propanoate
  参考文献：
  名称：

  The synthesis of an asparenomycin analog

  摘要：

  The synthesis of an analog of the carbapenem antibiotics, the asparenomycins, is described. This analog lacks the methyl group in the 6-alkylidene side chain while a methyl group has been placed at the 1-beta-position. The key step involved the Lewis acid-catalyzed rearrangement of an epoxide to an allylic alcohol.

  DOI：

  10.1016/s0040-4039(00)74477-7

文献信息

• Beta lactams as modulators of glutamate uptake and methods for use thereof
  申请人：Temple University—Of The Commonwealth System of Higher Education

  公开号：US10759750B2

  公开（公告）日：2020-09-01

  Pharmaceutical compositions of the invention comprise compounds, compositions, methods useful for the treatment of drug addiction, drug withdrawal, and diseases or conditions that involve dysregulation of glutamate homeostasis in its etiology.

  本发明的药物组合物包括用于治疗药物成瘾、药物戒断以及病因中涉及谷氨酸平衡失调的疾病或病症的化合物、组合物和方法。
• Substituted carbapenems for the treatment of bacterial infections
  申请人：ORCHID PHARMA LTD.

  公开号：US11180504B2

  公开（公告）日：2021-11-23

  This invention relates to carbapenem compounds of the following formula: wherein A, Z, X, R1, and R4 are as described herein, as well as stereoisomers, pharmaceutically acceptable salts or N-oxides thereof, which may be useful for the treatment of bacterial infections, particularly drug-resistant bacterial infections, as well as the processes for the preparation of compounds, the pharmaceutical compositions of these compounds and their use in the treatment of bacterial infection.

  本发明涉及下式的碳青霉烯类化合物： 其中 A、Z、X、R1 和 R4 如本文所述，以及其立体异构体、药学上可接受的盐或 N-氧化物，可用于治疗细菌感染，特别是耐药细菌感染，还涉及化合物的制备工艺、这些化合物的药物组合物及其在治疗细菌感染中的用途。
• [EN] CARBAPENEM COMPOUNDS<br/>[FR] COMPOSÉS DE CARBAPÉNÈME
  申请人：ORCHID PHARMA LTD

  公开号：WO2017158616A8

  公开（公告）日：2018-06-07
• Novel Beta Lactams as Modulators of Glutamate Uptake and Methods for Use Thereof
  申请人：Temple University-Of The Commonwealth System of Higher Education

  公开号：US20190127323A1

  公开（公告）日：2019-05-02

  Pharmaceutical compositions of the invention comprise compounds, compositions, methods useful for the treatment of drug addiction, drug withdrawal, and diseases or conditions that involve dysregulation of glutamate homeostasis in its etiology.
• CARBAPENEM COMPOUNDS
  申请人：ORCHID PHARMA LTD.

  公开号：US20200291029A1

  公开（公告）日：2020-09-17

  This invention relates to carbapenem compounds, their stereoisomers, pharmaceutically acceptable salts or N-oxides thereof, which may be useful for the treatment of bacterial infections, particularly drug-resistant bacterial infections, as well as the processes for the preparation of compounds, the pharmaceutical compositions of these compounds and their use in the treatment of bacterial infection.